{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resolution&page=47",
    "query": {
      "condition": "Resolution",
      "page": 47
    },
    "page_size": 10
  },
  "pagination": {
    "page": 47,
    "page_size": 10,
    "total_count": 1358,
    "total_pages": 136,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resolution&page=48&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resolution&page=46&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T14:23:54.038Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03492697",
      "title": "A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "PF-06882961 Immediate Release Tablet",
          "type": "DRUG"
        },
        {
          "name": "PF-06882961 Controlled Release Tablet (long)",
          "type": "DRUG"
        },
        {
          "name": "PF-06882961 Controlled Release Tablet (short)",
          "type": "DRUG"
        },
        {
          "name": "PF-06882961 Immediate Release Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 12,
      "start_date": "2018-04-30",
      "completion_date": "2018-07-18",
      "has_results": false,
      "last_update_posted_date": "2018-07-30",
      "last_synced_at": "2026-10-29T14:23:54.038Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03492697"
    },
    {
      "nct_id": "NCT02124278",
      "title": "Safety and Tolerability of Single Ascending Doses of PUL-042 Inhalation Solution in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PUL-042 Inhalation Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pulmotect, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 42,
      "start_date": "2014-02",
      "completion_date": "2014-10",
      "has_results": false,
      "last_update_posted_date": "2015-04-29",
      "last_synced_at": "2026-10-29T14:23:54.038Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02124278"
    },
    {
      "nct_id": "NCT01643226",
      "title": "Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Keratoconus"
      ],
      "interventions": [
        {
          "name": "riboflavin solution",
          "type": "DRUG"
        },
        {
          "name": "placebo solution",
          "type": "DRUG"
        },
        {
          "name": "KXL System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Glaukos Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 230,
      "start_date": "2012-07",
      "completion_date": "2016-09",
      "has_results": false,
      "last_update_posted_date": "2021-04-26",
      "last_synced_at": "2026-10-29T14:23:54.038Z",
      "location_count": 8,
      "location_summary": "San Diego, California • Indianapolis, Indiana • Overland Park, Kansas + 5 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Teaneck",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01643226"
    },
    {
      "nct_id": "NCT00128492",
      "title": "Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "AZLI 75 mg two times a day (BID)/ three times a day (TID)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 274,
      "start_date": "2005-08",
      "completion_date": "2009-01",
      "has_results": true,
      "last_update_posted_date": "2011-05-19",
      "last_synced_at": "2026-10-29T14:23:54.038Z",
      "location_count": 56,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 53 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00128492"
    },
    {
      "nct_id": "NCT02148068",
      "title": "Changes in Body Composition Following Bariatric Surgery",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Bariatric Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Peter Nau",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 136,
      "start_date": "2014-05",
      "completion_date": "2018-10",
      "has_results": false,
      "last_update_posted_date": "2018-11-20",
      "last_synced_at": "2026-10-29T14:23:54.038Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02148068"
    },
    {
      "nct_id": "NCT00333203",
      "title": "Next Generation Ophthalmic Irrigating Solution Posterior Segment Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Eye Diseases"
      ],
      "interventions": [
        {
          "name": "Next Generation Ophthalmic Irrigating Solution (NGOIS)",
          "type": "DRUG"
        },
        {
          "name": "BSS Plus",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 369,
      "start_date": "2005-10",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2012-03-05",
      "last_synced_at": "2026-10-29T14:23:54.038Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00333203"
    },
    {
      "nct_id": "NCT02287376",
      "title": "Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Diclofenac Potassium for Oral Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Depomed",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 25,
      "start_date": "2015-01",
      "completion_date": "2016-02",
      "has_results": true,
      "last_update_posted_date": "2017-07-25",
      "last_synced_at": "2026-10-29T14:23:54.038Z",
      "location_count": 2,
      "location_summary": "Tampa, Florida • Amherst, New York",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Amherst",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02287376"
    },
    {
      "nct_id": "NCT06904274",
      "title": "Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endometrial Hyperplasia"
      ],
      "interventions": [
        {
          "name": "BAY865028",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Medroxyprogesterone acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2025-11-24",
      "completion_date": "2026-06-17",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-10-29T14:23:54.038Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • West Hills, California + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "West Hills",
          "state": "California"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06904274"
    },
    {
      "nct_id": "NCT00629590",
      "title": "Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Blepharitis"
      ],
      "interventions": [
        {
          "name": "AzaSite®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2008-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-09-26",
      "last_synced_at": "2026-10-29T14:23:54.038Z",
      "location_count": 1,
      "location_summary": "Wantagh, New York",
      "locations": [
        {
          "city": "Wantagh",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00629590"
    },
    {
      "nct_id": "NCT02667288",
      "title": "An Open-Label Safety Study of A-101 Solution",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Seborrheic Keratosis"
      ],
      "interventions": [
        {
          "name": "A-101 Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aclaris Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 147,
      "start_date": "2016-01",
      "completion_date": "2016-10",
      "has_results": true,
      "last_update_posted_date": "2018-02-07",
      "last_synced_at": "2026-10-29T14:23:54.038Z",
      "location_count": 1,
      "location_summary": "Malvern, Pennsylvania",
      "locations": [
        {
          "city": "Malvern",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02667288"
    }
  ]
}